GYRE (Gyre Therapeutics) Interest Coverage: N/A (As of Mar. 2026)


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.30
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Gyre Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-6.8 Mil. Gyre Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.0 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Gyre Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Gyre Therapeutics's Interest Coverage or its related term are showing as below:


GYRE's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Gyre Therapeutics  (NAS:GYRE) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Gyre Therapeutics Interest Coverage Related Terms


Gyre Therapeutics Interest Coverage Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Gyre Therapeutics Interest Coverage Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
247.00 214.02 N/A N/A N/A

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

GYRE vs CBIO, RIGL, ARVN: Interest Coverage Comparison

For the Biotechnology subindustry, Gyre Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Interest Coverage falls into.


GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gyre Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Gyre Therapeutics's Interest Expense was $0.0 Mil. Its Operating Income was $11.5 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.3 Mil.

GuruFocus does not calculate Gyre Therapeutics's interest coverage with the available data.

Gyre Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Gyre Therapeutics's Interest Expense was $0.0 Mil. Its Operating Income was $-6.8 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.1 Mil.

GuruFocus does not calculate Gyre Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Interest Coverage: N/A
  • GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.30
Price
$9.82
GF Value